Introduction
The association of human papillomaviruses (HPV) and genital diseases is well established (Ho et al., 1998 ; Maiman et al., 1997 ; Nonnenmacher et al., 1995 ; Palefsky et al., 1998) . Mucosal low-risk HPV types are the causative agents of benign condylomata acuminata (Nouvo et al., 1991 ; Reid et al., 1987) ; in contrast, high-risk HPV types have been implicated in the pathogenesis of cervical intraepithelial neoplasia (CIN), vulvar Author for correspondence : Anton Petter.
Fax j43 512 504 4848. e-mail anton.petter!uibk.ac.at intraepithelial neoplasia (VIN), anal intraepithelial neoplasia (AIN) and anogenital cancer (Pfister et al., 1987) . HIV-infected persons are five times as likely to develop HPV-related diseases, such as CIN or AIN, as compared to HIV-negative individuals (Laga et al., 1992 ; La Ruche et al., 1998 ; Palefsky et al., 1998) .
Several studies have shown that HPV is mainly a transient cervicovaginal infection in immunocompetent individuals with a median duration of 8 months (Ho et al., 1998) . Indirect evidence suggests that primarily impaired cellular immune responses facilitate the development of persistent HPV infection and consecutive malignant transformation (Nakagawa et al., 1997 ; Shamanin et al., 1996) . Early, but not self-limited HPV infection with persistent virus shedding, as detected in a high proportion of cervicovaginal lavage specimens with HPV PCR, is considered to be critical for the development of intraepithelial neoplasia in women infected with human immunodeficiency virus (HIV) (Sun et al., 1997) .
DNA detection assays such as PCR for HPV are expensive and time-consuming. Moreover, these methods are not sufficient to exclude prior HPV exposure. In latency, viral DNA could persist in clinically unsuspicious regions from various anatomical areas where specimens for screening are not routinely obtained. Serological HPV assays could supply additional information to identify persons at risk of HPVrelated cancers. Papillomavirus L1 capsid proteins that selfassemble into virus-like particles (VLPs) are effective antigens for serological studies and can be used to detect type-specific humoral immune responses in patient sera (Heim et al., 1995 ; Kirnbauer et al., 1992) . It is important to note that the recognized antibodies directed against VLPs are thought to neutralize infectious viruses in model systems (Christensen et al., 1994) . However, neutralizing antibodies do not induce regression of established infection in animal models.
So far, studies on serum antibodies to HPV capsids have focused on HPV seroprevalence in immunocompetent women Heim et al., 1995 ; Kirnbauer et al., 1994 ; Nonnenmacher et al., 1995) and HIV-infected men (Hagensee et al., 1997) indicating no lack of humoral immunity in the latter patient group. We are not aware of any study analysing HPV-specific antibodies in immunosuppressed HIVpositive women. The aim of our study was to evaluate humoral (IgG, IgA and IgM) responses to intact HPV L1 VLPs of in women infected with HIV.
Methods
Patients and specimens. The AIDS Outpatient Clinic at the University of Innsbruck is the only primary care and referral centre for patients with HIV\AIDS in the Austrian Tyrol. Nearly all of the patients with AIDS ( 95 %) reported to the health authorities are in treatment at this AIDS Outpatient Clinic. Eighty-three of 102 women known to be HIV-infected (aged 22-72 years, median 37) were regularly seen at our gynaecological outpatient department. Gynaecological data (between October 1987 and April 1998) were available from these women and all of them were included in our analysis. Each subject underwent routine gynaecological examinations, including colposcopy and cervical smears for cytology, at intervals of at least 3-12 months. Cytological classification followed the Munich classification system [i.e. Papanicolaou (Pap) IIID, signs of mild or moderate dysplasia, CIN I or CIN II ; Pap IV, signs of severe dysplasia or carcinoma in situ, CIN III] . Hybrid capture HPV DNA data for high-and low-risk HPV DNAs were obtained in 58 cases. Eighteen patients received surgical treatment at our clinic. PCR analysis and sequencing for HPV typing was done with formalin-fixed paraffin-embedded tissues from all 18 surgically treated patients.
Control subjects. Sera from 102 female patients (aged 22-67 years, median 35), randomly chosen from HIV-negative women visiting the gynaecological outpatient clinic representing a cross-section of women attending a university hospital in Austria, with no bias towards social or economic status were analysed. The reasons for consulting the clinic were routine gynaecological examinations, e.g. to receive oral contraceptives. Patients with drug abuse, malignancies, pregnancies, pelvic inflammatory disease, pathological PAP smears and existing or previous HPV-related diseases (e.g. genital warts, CIN, VIN) were excluded. In 36 of these women, an HPV PCR test (genital swab) was performed and was negative. An additional control group with HPV-associated diseases consisted of 48 non-pregnant, HIV-negative women (aged 20-72 years, median 32n5) with intermediate-or high-grade CIN, including 14 patients with CIN III and six cases with invasive cervical cancers. The majority of these patients were high-risk HPV DNA-positive.
HIV serology. Sera were screened for HIV antibodies using the Enzygnost Anti-HIV-1\2 ELISA (Behring) and confirmed by Western Blot (Du Pont or Biotechnologies) in at least two different samples.
Sampling. Serum samples for HPV analysis obtained from all women were frozen, preserved at k80 mC and used later for HPV serology.
HPV DNA typing and HPV PCR analysis. Nucleic acid hybridization tests (Digene Diagnostics) were performed from cervical or vulvar smears according to the manufacturer's instructions for the presence of HPV-6\-11\-42\-43\-44 (low-risk) and HPV-16\-18\-31\-33\-35\-45\-51\-52\-56 (high-risk) DNA in cervical and vulvar smears. PCR was performed as follows. Formalin-fixed paraffin-embedded tissues were processed with the QIAamp Tissue kit (Qiagen) according to the manufacturer's instructions. Purified total cellular DNA (10 µl) was employed in each PCR reaction (25 ng\µl). Cervical scrapes of patients were processed as described by Van den Brule et al. (1990) . GP5j\6j general primer PCR and TS6, TS11, TS16, TS18 and TS31 type-specific PCRs were then performed as previously described (Van den Brule et al., 1990 ; De Roda Husman et al., 1995) . Samples negative for GP5j\6j were additionally analysed with a more sensitive nested PCR for the detection of genital HPVs. Degenerate primers A5 (5h TAT TYT SCT WCT CCY AGT GG 3h, HPV-16 L1 gene nt 871-890) and A10 (5h CKT CCC AAR GGA WAY TGR TC 3h, HPV-16 L1 gene nt 1397-1378) were used for first-step PCR. A6 (5h GCM CAG GGM CAY AAY AAT GG 3h, HPV-16 L1 gene nt 946-965) and A8 (5h CAA ART TCC ART CYT CCA A 3h, HPV-16 L1 gene nt 1213-1196) were used for secondstep PCR. A6 and A10 are modified My11 and My09 primers, respectively (Bauer et al., 1991) . First-step amplification reactions were performed in 50 µl containing 50 mM KCl, 10 mM Tris-HCl (pH 8n8), 3n6 nM MgCl # , 0n05 % (w\v) gelatin, 200 µM of each dNTP (Boehringer Mannheim), 2n5 units Taq DNA polymerase (Pharmacia), and primers A5 and A10 (0n5 µM each). Second-step amplification reactions were performed in 50 µl containing 50 mM KCl, 10 mM Tris-HCl (pH 9n0), 1n5 mM MgCl # , 200 µM of each dNTP, 2n5 units Taq DNA polymerase, and primers A6 and A8 (0n5 µM each). Three microlitres from the firststep PCR was used as input for the second-step PCR. Cycling conditions for first-step PCR were 95 mC for 3 min followed by five cycles of 95 mC for 45 s, 50 mC for 45 s and 72 mC for 1n5 min, followed by 30 cycles of 95 mC for 45 s, 56 mC for 45 s and 72 mC for 1n5 min. Cycling conditions for second-step PCR were 95 mC for 3 min, followed by 35 cycles of 95 mC for 45 s, 56 mC for 45 s and 72 mC for 1n5 min. The size of the second-step PCR product (A6\A8) was 271 bp. PCR products (5 µl) were separated on 3 % agarose gels and visualized by ethidium bromide staining. To avoid PCR contamination, the suggestions of Kwok (1990) were diligently considered. Five negative controls (water instead of patient samples and patient samples known to be HPV-negative) were included in each PCR run. HPV typing was either performed by typespecific PCRs (Van den Brule et al., 1990) or by direct sequencing of PCR products and comparison of the obtained sequences with an HPV HAC database (Myers, 1997) . Direct sequence analysis of purified PCR products (QIAquick PCR purification kit ; Qiagen) was performed with an ABI Prism 377 DNA sequencer using the Taq FS BigDye-Terminator cycle sequencing method (PE Applied Biosystems). Depending on the PCR product to be sequenced, A6 or GP5j was used as sequencing primer.
Preparation of baculovirus-expressed VLPs. Recombinant baculoviruses expressing HPV-6 L1 (a gift of A. B. Jenson, Georgetown University, Washington, DC, USA), HPV-11, -16, -18 and -31 L1 and bovine papillomavirus (BPV)-1 L1 protein-expressing baculoviruses (provided by J. T. Schiller, National Institute of Health, Bethesda, MD, USA) were produced as previously described (Kirnbauer et al., 1992 ; Christensen et al., 1994) . The method of VLP purification has also been described previously (Christensen et al., 1994) .
MAbs. Type-specific MAbs (H6.B10, H11.B2, H16.V5, H18.R5, H31.A6 and B1.A1) recognizing surface conformational epitopes on intact HPV-6, -11, -16, -18, -31 and BPV-1 L1 VLPs as control antigens, respectively, were generated as described previously (Christensen et al., 1996 a, b) . They were used as positive controls in serological assays.
HPV ELISA. , -31 and BPV-1 L1 VLPs were used as antigens in direct ELISAs. The method was previously described (Kirnbauer et al., 1992 ; Christensen et al., 1994) . Briefly, VLPs diluted in PBS (1 µg VLP protein in 100 µl PBS) were attached to wells of roundbottom ELISA plates (Nunc Brand Products and Petra Plastic 96 rounded wells γ-sterilized Typ F, ELISA 11041 E) by incubating 90 µl VLP solution per well at room temperature for 45 min. VLP-free PBS-incubated wells were used as negative control wells. All plates were washed three times with PBS (SLT Labinstruments 812 SW2) and were incubated with 200 µl milk buffer (1 g Fixmilch Instantj20 ml Dulbecco's PBS) per well for 30 min (room temperature). Patient sera were heat-inactivated at 56 mC for 30 min and used at a final serum dilution of 1 : 100. Each patient's serum (25 µl) and positive and negative controls were tested in duplicate wells and incubated for 1 h and then washed again three times. MAbs (100 µl) corresponding to VLP types (positive control wells) were diluted with 5 % milk buffer (final dilution of 1 : 200). Subsequently, the wells were incubated with goat anti-human IgG (1 : 10 000), IgA (1 : 2000) , IgM (1 : 2000) and RαM (1 : 1000) antibodies (Sigma). After incubation for 30 min (room temperature), the wells were washed three times and substrate (Tris buffer with p-nitrophenylphosphate tablets) was added. Absorbances at 405 nm were read on a microplate reader (SLT Labinstruments 400 ATC ; Software Easy-Fit) 30, 60 and 90 min after adding substrate. Means and SD of duplicate wells were calculated as final A %!& values for each serum sample.
Statistical methods.
In all experiments, patient and control sera were analysed together. Means and SDs of ELISA absorbency values of the control group were used statistically to define positive and negative patient sera for each target antigen (HPV-6, -11, -16, -18, -31 and BPV-1) and serum antibody isotype (IgG, IgA and IgM) . Individual values in the control group exceeding the meanj(3iSD) were excluded and the remaining readings were averaged again until no further values exceeded the recalculated meanj(3iSD). Samples with values greater than the recalculated final meanj(3iSD) were designated positive for reactivity to the appropriate antigen in the current experiment. For scalar variables, the non parametric Mann-Whitney U test was used for statistical analysis, because group A %!& values had an asymmetric distribution ; Fisher's exact test was used for categorical variables. P 0n05 (twotailed) was considered statistically significant. All calculations were done with SheePS Counting Software (SPSS) 7.0 for Windows 95.
Results

Patient characteristics
Patient characteristics are given in Table 1 . Twenty-five (30 %) of the 83 HIV-positive women had AIDS and one woman died as a consequence of cervical cancer. Of the HIVinfected women, 55 % had a history of antiretroviral therapy ; however, 24 % of these were protease inhibitor-naive. HPV-related diseases were seen in 30 of 83 HIV-infected women (36 %). In 21 women (25 %), intermediate-or highgrade CIN and\or VIN was diagnosed. The median CD4 cell count at the time-point of first detection of HPV-related lesions (253 per µl ; range 45-697) was lower than the median CD4 count on the day when the serum sample for HPV serology was taken (331 per µl ; range 5-1075), but this difference was not significant (P l 0n5).
HPV DNA analysis
Data on cervical and vulvar smears of 58 HIV-infected women, routinely analysed for the presence of HPV DNA by nucleic acid hybridization tests (Digene), were available at different times (at least one up to eight samples per woman). Cumulative prevalences were as follows. Thirty-one (53 %) of the 58 women with hybridization data were positive for high- risk HPV DNA and twenty-two (38 %) were positive for low-risk HPV DNA. Women with a positive nucleic acid hybridization test for high-risk HPV types remained positive in consecutive tests (mean observation period 35 months) with the exception of four women. One of them became spontaneously negative and three became negative during the follow-up after surgery of HPV-related lesions. HPV PCR data were obtained from 20 HIV-positive women (Table 2) . Paraffin-embedded material was used from all 18 women presenting with HPV-related lesions requiring surgical treatment. Cervical scrapes were obtained from seven women. In five of them, an overlap with paraffin material allowed analyses of smears and tissue in the same patient at two timepoints. PCR results were identical in corresponding paraffin and smear samples. Samples of 18 out of 20 patients (90 %) were PCR-positive for HPV. Eleven cases (55 %) were positive for high-risk HPV DNA. HPV-16 and related types (HPV-31, -33, -35 and -58) were found in 10 women (50 %) ; HPV-18 and the related HPV-45 were in one patient each. HPV-34, -40 and -74 were detected in three samples ; all of them represent extremely rare HPV types. HPV-52, which is common in China, and HPV-39, which is almost entirely confined to Central and South America, were found once each. More than one HPV type (HPV-6, -18 and -31) was seen in paraffinembedded material of one woman. In one sample, the HPV type could not be determined with PCR analysis.
PCR was performed in 45 of 48 HIV-negative, CIN\cancer control patients and revealed HPV DNA in 38 cases (84 %). High-risk HPV DNA was detected in 33 cases (73 %) and lowrisk HPV DNA was found in eight cases (17 %) with double infection in three individuals. Typing by sequencing demonstrated HPV-16 DNA in 17 patients (37 %). HPV-35 was found in three cases, and HPV-52 and -58 were observed in two cases each. were each found once and, in the remaining cases, the HPV type was not further determined.
HPV ELISA : comparison of HIV-positive and HIV-negative women
HIV-positive women were significantly more likely than HIV-negative women to have detectable levels of antibodies to both high-risk (HPV-16, -18 and -31) and low-risk (HPV-6 and -11) HPV VLPs. Overall seropositivity rates are summarized in Table 3 . Fig. 1 illustrates IgG seroreactivities to several HPV types in four patient groups. For example, 49 % of HIV-positive women were seropositive for HPV-16 IgG versus 31 % of HIV-negative CIN\cancer women (with known exposure to HPV). This difference was statistically significant (P l 0n046). A trend was seen for HPV-18 (P l 0n058). HPVspecific antibodies were detected in 20 of 38 HPV DNApositive, HIV-negative, CIN\cancer patients (55 %) and in 15 of 18 HPV DNA-positive, HIV-positive women with HPVassociated diseases (83 %). No significant reactivities were seen with the BPV control antigen.
HAE
HPV ELISA : analyses within the HIV-positive cohort
The detection of high-risk HPV IgG antibodies was more common (though not statistically significant) in HIV-infected patients with clinically evident HPV-related diseases compared with women without genitoanal HPV lesions. An obvious trend (P l 0n07) was seen for HPV-16 antibodies which were more likely detected in patients with HPV-related lesions. Interestingly, women with a history of one or more positive HPV DNA hybrid capture result were not more likely to have any HPV antibodies detected than women with negative HPV DNA tests. We found an antibody detection rate of 83 % in 18 HIV-positive, HPV DNA-positive women with HPVassociated diseases which was also not significantly higher than that seen in 21 HIV-positive, HPV DNA-negative women without HPV-related disease (66 %, P l 0n17). Mean CD4 cell counts on the day of serological testing had no influence on HPV IgG, IgA or IgM antibody responses, as had prior antiretroviral therapy, clinical category of HIV disease or history of drug abuse.
HPV ELISA : type-specificity
Serotype and sequencing data corresponded most obviously when analysing HPV-16. For example, four of six HPV-16 PCR-positive, HIV-positive women (66 %) were also HPV-16 IgG seropositive ; the two others revealed serotype 18 or 31 (Table 2) . Similarly, nine of 15 HPV-16 PCR-positive, HIV-negative CIN\cancer patients were also HPV-16 IgG seropositive (60 %). In five of these nine sera, in addition, HPV-16 IgA antibodies were detected. Antibodies to HPV types other than HPV-16 were rarely detected in this subgroup of HPV-16 PCR-positive patients : HPV-18, -31 and -11 antibodies were present in two patients each (13 %), and HPV-6 antibodies were detected once. In contrast, HPV-16 antibodies were seen only in four of 14 HIV-positive, HPV-16 DNAnegative women (28 %) and in four of 30 HIV-negative, HPV-A. Petter and others A. Petter and others 16 DNA-negative CIN\cancer patients (13 %). IgG, IgA and IgM reactivity to more than one high-or low-risk HPV type was not more likely in HIV-infected women compared to HIVnegative controls with or without HPV-associated diseases, indicating that the specificity of the serum ELISA test was similar in these two patient groups. Double IgG or IgA reactivity (defined as one serum reactive to two different HPV types) was seen preferentially within the groups of high-or low-risk HPV types in both HIV-positive and -negative patients. For example, in HIV-positive women, 42 sera were IgG-reactive to either HPV-6 or HPV-11, and 29 % were found to be positive for both HPV-6 and -11. In HIV-negative women, this percentage was 31 %. Double reactivity was less common (P l 0n069 in the two-tailed Fisher's exact test) between the two groups of high-or low-risk HPV types. When, for example, IgG-6 (low-risk type) and IgG-16 (highrisk type) positivity was analysed, the percentage of double reactivity was only 12 % in HIV-positive and 11 % in HIVnegative sera. These trends were seen with all the VLP types. IgM reactivity was found to be far less type-specific, e.g. IgMpositive sera reacted in 44 % with both HPV-6 and -16 ; in comparison, this percentage is much higher than observed and mentioned above with IgG and identical HPV-6 and -16 VLPs (12 %).
HPV ELISA : antibody reactivity over time
The time-course of seroreactivity was retrospectively analysed in 29 HIV-infected women with a diagnosis of HPVrelated lesions. The mean observation period was 35 months (range 3-76). Twenty-three women (79 %) were seropositive to any high-risk HPV-IgG at baseline ; 17 of these remained positive in consecutive tests. Of six women (21 %) seronegative for all high-risk HPV IgG antibodies at baseline, five had no history of HPV-related lesions at that time. These five women remained negative in consecutive tests, although lesions developed. The results for low-risk HPV IgG VLPs were as follows. Ten women (34 %) were seropositive at baseline ; seven of these remained seropositive throughout the study. Seronegativity at baseline was seen in 19 women (66 %) and remained negative in consecutive tests ; seroconversion was only observed in one exception. Appearance of HPV-related lesions or treatment actions (e.g. surgical excision, laser therapy) seemed to have no influence on serological status.
Discussion
Despite partial restoration of immune functions as a result of highly active antiretroviral therapy (Heard et al., 1998) , HPV-associated malignancies may become a major problem in the future, because of rising life expectancy in HIV-positive patients (Palefsky et al., 1998) . A significantly higher prevalence of HPV DNA in HIV-positive cases compared to HIV-negative controls has been described (Laga et al., 1992 ; Wright et al., 1994) , but not confirmed by others (Braun et al., 1994 ; Cappiello et al., 1997) . It was also reported that HPV DNA prevalence was largely independent from the level of immunosuppression (Cappiello et al., 1997) . It was therefore proposed that HIV induces CIN by increasing the transforming activity of oncogenic HPV types (Buonaguro et al., 1994 ; Cappiello et al., 1997) . However, there is little evidence in vivo to support such a model of association. Prolonged exposure to HPV proteins could be an alternative mechanism. This hypothesis is suggested by results of repetitive HPV DNA testing of cervicovaginal lavage specimens in HIV-infected women (Sun et al., 1997) . Immunosuppression may promote a high rate of persistent shedding of HPV particles.
The present study is, to the best of our knowledge, the first published analysis of the specific humoral immune response against HPV particles in HIV-infected women. Our clinical and DNA data confirm a high prevalence of HPV-related lesions in HIV-infected women in the previously documented range (La Ruche et al., 1998) . In addition, we have shown that HIVinfected patients are able to generate a vigorous anti-HPV serological response. Published results available for HIVnegative individuals reveal, in general, that high seropositivity rates are associated with clinically evident HPV lesions and\or detectable HPV DNA. Wideroff et al. (1995) reported the detection of HPV-16 VLP antibodies in 31 % of patients with low-grade and in 52 % of patients with high-grade cervical lesions. Kirnbauer et al. (1994) found 59 % seropositivity with HPV-16 VLPs in patients with HPV-16 DNA PCR-positive lesions. In line with these published results, we found 60 % seropositivity with HPV-16 VLPs in HPV-16 PCR-positive, HIV-negative women and 66 % seropositivity in HPV-16 PCR-positive, HIV-positive women. Even in HIV-positive women without clinically evident HPV lesions there was, compared to healthy HIV-negative controls, a highly increased seropositivity rate with high-risk HPV VLPs (47 % versus 19 % ; P l 0n0001). The data remained statistically significant (P l 0n0002) when woman with a history of drug abuse, a well-known single risk factor for sexually transmitted diseases (Fenaughty & Fisher, 1998 ; Siegal et al., 1996) , were excluded as a confounding factor. The HPV seropositivity rate in the HIV-positive cohort was even higher (P l 0n046 for HPV-16 IgG) than in the control group of HIV-negative women with HPV-associated diseases. Since prolonged exposure to viral antigens is thought to be a primary determinant of a detectable antibody response our data suggest that HIV-positive women are intensely exposed to HPV proteins throughout the natural course of their HIV infection. Cellular immunosuppression could facilitate the occurrence of complete life-cycles of HPV and subsequent capsid antibody induction.
Nearly half of the women were seropositive for more than one HPV type. This could reflect cross-reactivity or infection with multiple HPV types. At least in part, it seems to be likely that the data indicate infection with multiple HPV types in HIV-positive and HIV-negative individuals, since we have demonstrated previously that type-specific IgG antibodies exist, which discriminate even the closely related HPV-6 and -11 (Heim et al., 1995) . The role of HPV IgA and IgM isotypes in clinical practice remains to be determined in future studies. The isotype IgA is an immunoglobulin predominantly produced in submucosal lymphoid tissues and is expected to be highest in cervicovaginal secretions. However, even in serum, the prevalence of HPV IgA antibodies was relatively high in comparison to IgM antibodies. The frequency and type specificity of the latter isotype was generally low, and therefore there was no evidence of a time correlation between HPV IgM seroconversion and recent HPV infection, as is known from other infections.
Detectable HPV antibodies did not correlate strictly with HPV DNA results. One must consider that antibody responses also reveal past exposure to virus. It is also possible that, with increased time of HIV infection, there is a decrease in the responsiveness to the more recent HPV infections. Serotype and HPV type responsible for the disease at the date of serology may therefore not be identical.
In summary, we conclude that the high prevalence of HPV antibodies reflects a high lifetime cumulative exposure to HPV associated with clinical disease in HIV-positive women. This may be due to high-risk sexual behaviour and defects in the cellular control of HPV. However, even in immunosuppressed HIV-positive women, a humoral immune response to HPV is clearly detectable and the test has turned out to be as sensitive in HIV-infected individuals as has been shown previously for immunocompetent individuals Heim et al., 1995 ; Kirnbauer et al., 1994) . Therefore, HIV-infected patients may be candidates for future prophylactic vaccination strategies. The impact of HPV serology on diagnostic strategies in HIV-infected individuals remains to be determined.
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